Users request mandatory licensing for obesity drugs

The UMG advocates for mandatory licenses to improve access to obesity medications, arguing that a 15% subsidy is insufficient. They emphasize the need for legal mechanisms to ensure affordable treatment options, citing the economic burden of obesity in Portugal. The association highlights the success of generics in reducing costs for diabetes medications and calls for timely entry of cheaper alternatives, referencing Brazil's recent approval of generics after patent expiration. UMG stresses that obesity should be addressed as both a public health issue and an economic challenge, requiring effective policies for prevention and treatment.